Breaking News

Lonza Restructures CDMO Business

Three new business platforms, Integrated Biologics, Advanced Synthesis, and Specialized Modalities, aim to create a unified organization.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

At its Investor Update 2024, Lonza announced an organizational restructuring based around four key initiatives: Focus on the CDMO business; Reshape the operating model; Elevate execution in manufacturing and engineering; and Expand through an impartial approach to buy and build. The strategy aims to protect and enhance key Lonza business strengths, including cutting-edge science and technology for emerging and complex modalities, and a critical mass of assets in key strategic regions.   The or...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters